Since high expression of SIK2 appears in various cancers due to an amplified region in the chromosome 11q23, SIK2 is considered as a potential oncogenic marker for ovarian and prostate cancers, as well as glioma and diffuse large B-cell lymphoma (DLBCL).6,10–12 To date, SIK2 has been proved to promote tumorigenesis by modulating many aspects of cancer hallmarks (Fig. 4). Here, SIK2 is linked to cancer.